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Summary 
3CL-Pro (or M-Pro) is the SARS-CoV-2 main protease, responsible for the cleavage of the large 
polyprotein 1ab transcript and the liberation of eleven proteins, responsible for viral growth and 
replication. It acts exclusively as a homodimer, while monomers are inactive. Due to its pivotal role, 
3CL-Pro has been one of the most studied SARS-CoV-2 proteins and the subject of a number of 
therapeutic interventions, targeting its catalytic domain. A number of potential drug candidates have 
been reported, including some natural products. Here, we have investigated in silico, through fully 
flexible binding and extensive molecular dynamics simulations, the natural product space for the 
identification of potential candidates of 3CL-Pro dimerization inhibitors. We report that fortunellin 
(acacetin 7-O-neohesperidoside), a natural flavonoid O-glycoside, isolated from the fruits of Citrus 
japonica var. margarita (kumquat), is a potent inhibitor of 3CL-Pro dimerization. A search of the ZINC 
natural products database identified another 16 related molecules, which possess interesting 
pharmacological properties. We propose that fortunellin and its analogs might be the basis of novel 
pharmaceuticals against SARS-CoV-2 induced COVID-19 disease. 
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Significance statement 
We identified fortunellin, a natural product from kumquat and its analogs, as inhibitors of the 
dimerization of the SARS-CoV-2 main protease 3CL-Pro, which might lead to the development of novel 
pharmaceuticals against COVID-19 disease.  
Introduction 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019, 
and is the causative agent of coronavirus disease 2019 (COVID-19). It became a global pandemic, 
threatening the lives of millions of people belonging to sensitive health groups. Based on the World 
Health Organization (WHO) as of 6 July 2020, more than 11.4 million cases of COVID-19 have been 
reported in more than 188 countries and territories, resulting in more than 533,000 deaths. Intense 
scientific effort worldwide resulted in the identification of SARS-CoV-2 genomic structure, viral protein 
sequence and structure and disease characteristics (1, 2). The SARS-CoV-2 genome, very close to that 
of the severe acute respiratory syndrome coronavirus (SARS-CoV) (2), contains genes encoding 3C-like 
proteinase, RNA-dependent RNA polymerase (RdRp), 20-O-ribose methyltransferase, spike protein, 
envelope protein, nucleocapsid phosphoprotein, and several polyprotein complexes of known or 
unknown function (https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/). SARS-CoV-2 3CL-Pro 
plays a key role in polyprotein processing. It acts as a homodimer (3), and its structure is similar to the 
crystal structure of other coronaviruses main proteases (see reference (4) for a review, and references 
herein). This enzyme plays a vital role in cleaving the large polyprotein 1ab (replicase 1ab, ∼790 kDa) 
translated by the virus RNA, at 11 different sites, liberating proteins indispensable for viral replication 
and proliferation, with a unique specificity, not found in any human protease (5). Therefore, it 
represents a preferential target for the development of a series of not toxic inhibitors. 
The individual monomers of SARS-CoV MPro are inactive, and two strategies have been employed to 
develop enzyme inhibitors: (i) molecules targeting the substrate binding pocket, to block its catalytic 
activity, and (ii) dimerization inhibitors. A significant effort targeted the inhibition of the enzymatic 
activity (201 substances were recorder in the ChEMBL database as per July 9, 2020 for the SARS-CoV-
2 3CL-Pro, and a number of molecules, active on SARS-CoV protease and reviewed in Reference (6), 
including also natural products  (7). In contrast, only scarce reports address the issue of SARS-CoV 3CL-
Pro (8, 9), and none of SARS-CoV-2. Here we have initiated an in silico study, in view of analyzing the 
dynamics of the monomeric and the homodimeric protein, and exploring possible natural 
polyphenolic compounds as potential inhibitors of the protein homo-dimerization. Our results 
returned the natural product fortunellin as a lead compound, which could be used as the basis for the 
design of novel antiviral compounds. 
 
 
  
Results 
The dynamics of 3CL-Pro monomer and homo-dimer 
The 3CL-Pro (or MPro) is one of the most studied SARS-CoV-2 proteins, due to its pivotal role in the 
mode of action of the virus. Indeed, the role of this protease in the cleavage of the coronavirus 
replicase polyprotein 1ab at eleven conserved sites, giving rise to eleven specific proteins, responsible 
for the majority of viral actions. This increased interest in this molecule is testified by the existence, in 
the Swiss Model Biospace of 110 different crystal structures, deposited in the protein data bank (July 
2020). Their corresponding codes are presented in Supplemental Table 1. These models, as an 
apoprotein, or bound to a number of ligands, show a great structural similarity. An example of 
comparison of 10 different crystals is presented in Supplemental Figure 1, together with the 
corresponding Root Mean Square Deviations (RMSD). 
For the purpose of this work, and in view of the very small differences of the 3CL-Pro crystals, we have 
used the 6YB7 unliganded crystal, analyzed with X-ray diffraction. Interestingly, using the GalaxyWeb 
server, routine refine, we obtain the same 3D protein structure, based on the same 6YB7 crystal 
template. Employing this conformation of the proteinase, along with that of the 6LU7 crystal in order 
to increase the conformational phase space sampling, we have performed a molecular dynamic (MD) 
study for long time periods (70 μs), and a subsequent Markov State Modeling (MSM) on the 
trajectories. Based on the MSM analysis of the equilibrium MD trajectories, we obtain three 
macrostates, or conformational states of the monomeric protein, as shown in Figure 1A. 
The MPro acts as a Cyclic-C2 (Global Symmetry) Homo-dimer (10-13). Here, we further simulated the 
dimeric structure of the SARS-CoV-2 protein, with two independent methods: (1) we used the 
GalaxyWEB server, routine HOMOMER (http://galaxy.seoklab.org/cgi-
bin/submit.cgi?type=HOMOMER) for the MPro protein oligomer structure prediction from a 
monomer sequence or structure (Oligomeric state = 2); (2) the HEX  8.0 program (http://hex.loria.fr/), 
a locally executed software, for protein-protein, or protein-nucleic acid interactions, based on 
spherical rotated protein complexes, taking into account both surface shape and electrostatic charge. 
We compared our results with the X-ray diffraction crystal solution (pdb 6YB7, Supplemental Figure 
2). As shown, a very good homology was found, with global RMSD ~0.5 Å, confirming the validity of 
our approach. MD of the homodimer of 3CL-Pro (10μs), followed by 10μs parallel-tempering 
metadynamics at the well-tempered ensemble (PTmetaD-WTE) (Figure 1B), revealed three 
conformations of the homodimer, as derived by minimal surface energy conformations, with the 
Collective Variable (CV) phase space determined by the torsional angles of residues 3, 4, 5, 6, 84, 135, 
141, 164, 167, 171, 175, 178, 179, 180, 190, 195, 217, 284, 285, 286, 290, 291, 300, and 301. Please 
refer to Supplementary Methods, for the detailed conformational space functions out of the MSM 
analysis. The first conformation (C1) corresponds to the crystal structure of the dimer (monomer 
distance 1.72-1.78 Å), while the other two (C2-C3) correspond to dimer structures with higher (1.86-
1.93 Å) distances among monomers, resulting in decreased monomer-monomer interactions (see 
Figure 2D). The monomer distances have been calculated based on the minimum distances between 
residues on the monomer-monomer interface (4, 10, 11, 14, 28, 139, 140, 147, 290, 298) (4).  
Fortunellin is a natural product that inhibits 3CL-Pro dimerization 
The identified dimerization surface of 3CL-Pro proteinase was used as a binding groove for the 
detection of possible natural small molecules, acting as inhibitors of dimerization.  We have 
interrogated the FTMap server (http://ftmap.bu.edu) (14), which uses the pdb structure of a protein 
as a scaffold and uses a series of 16 small molecular probes in order to identify binding hot spots, 
determine drugability and provide information about fragment-based drug discovery (15). The results 
of FTMap permit us to design a minimal structure of a potential 3CL-Pro dimerization inhibitor. 
Interrogating the ZINC database of natural products (https://zinc.docking.org/) with this minimal 
structure, we have identified fortunellin (ZINC4349204, Figure 2A) as a potential natural inhibitor of 
3CL-Pro dimerization. Binding of fortunellin on the monomeric 6YB7 monomer of 3CL-Pro (Figure 2B) 
revealed a high affinity binding (ΔG -13.9 kcal/mol) using the fully flexible GalaxyWeb server, and a 
binding at the dimerization interface, with significant interactions with amino acids related to the 
dimerization of the molecule (Leu32, Asp33, Asp34, Val35, Tyr37, Gln83, Lys88, Tyr101, Lys102, Phe103, Val104, 
Arg105, Asp108, Phe159, Cys160, Asp176, Leu177 and Glu178). Interestingly, fortunellin-bound 3CL-Pro 
monomer cannot form a dimer with free 3CL-Pro, as assayed with the HEX algorithm. 
We have used the different poses of the monomeric 3CL-Pro MD solutions for 60 μs, at 1 ns intervals 
(poses were retrieved every 3 μs) as scaffolds for fortunellin binding (Table 1, Figure 2C). As shown, 
the affinity of fortunellin is fluctuating around -12.3 kcal/mol (SD ±1.005 kcal/mol), and, after initial 
fluctuations, preceding significant changes of the dimerization domain, as expressed by changes of 
the local RMSD value, as compared to the crystal structure of 3CL-Pro, it stabilizes after 60 μs. In 
addition, an MSM analysis of the dynamics of MPro, in the presence and absence of fortunellin, were 
also performed to refine the conformational phase space and further reduce the degrees of freedom, 
compared to the initial MSM on the monomer. In Figures 2D-E, we present the three MPro states in 
the presence and absence of fortunellin, respectively on the same refined phase space (CV-1/ CV-2). 
The C1-C3 minima are assigned in these graphs based on structural feature comparison with Figure 
1B. Based on MSM, we calculated that the transitions between the different states (C1-C3) occur at 
the average time scales of 37.6ns (slow processes) and  3.5ns (fast processes) in the absence of 
fortunellin (Figure 2F). However, the average transition time scale in the presence of fortunellin drops 
to 1.42ns with only fast transitions (Figure 2G). This significantly smaller time-interval results in greater 
energy changes faster in the presence of fortunellin, blocking the trapping at certain states, and 
inhibiting the formation of the dimer by sampling non-favorable monomer conformations, i.e. with 
greater distance among monomers, that favor its dissociation. We note that the C1 minimum that is 
associated with the crystal structure (active for dimerization) in Figure 2D, it is absent in Figure 2E, 
indicating that fortunellin disfavors this state. Instead, C1 is displaced by an alternative protein state, 
indicated by the purple area in Figure 2E. 
It appears therefore that the natural polyphenol fortunellin disrupts the dimerization of the main 
SARS-CoV-2 main protease 3CL-Pro and therefore is a good drug (or dietary supplement) candidate 
for combatting COVID-19 disease. 
Research of other natural products with similar structure to fortunellin 
Interrogating the ZINC database for natural products with fortunellin as a bait, we have retrieved 16 
natural compounds with similar molecular properties, presented in Table 2. They were tested for 
binding to the dimerization domain of the 3CL-Pro monomer, and found to possess an affinity similar 
or higher to that of fortunellin. Their absorption, distribution, metabolism, and excretion (ADME) 
characteristics were evaluated in the SwissADME site (16), and the results are shown in Supplemental 
Table 2. It derives that they are all water-soluble compounds, with limited enteric and skin absorption, 
but they are non-toxic, as they are not predicted to interact with the CYP drug metabolizing enzymes. 
 
  
Discussion 
Awaiting for an efficient vaccine for the prevention of COVID-19 disease, scientific efforts are directed 
towards repurposing known drugs, or developing new ones, against key viral proteins, involved in the 
viral replication and proliferation (17, 18). In addition of targeting proteins involved in viral recognition 
and entry into the human cells, a significant effort is directed towards viral proteins involved in the 
replication and proliferation of the virus. One such protein is the SARS-CoV-2 3CL-Pro (or main 
protease-MPro), a pivotal enzyme, acting exclusively as a homodimer  (3) and implicated in the 
cleavage of the large polyprotein 1ab, liberating 11 different proteins indispensable for viral 
replication and proliferation (5). However, the bulk of the scientific effort targets the discovery or 
repurposing of inhibitors of its enzymatic activity. Here, we have taken another approach, directing 
our efforts toward the identification of (natural) compounds, which could inhibit the dimerization of 
the enzyme, indispensable for its biological activity. At a first step, beginning with the published crystal 
structure of the protein (19), we performed a molecular dynamics study, combined with Markov state 
model (MSM) theory (20). This enables the extraction of long-time-scale individual monomer 
dynamics from rather short-time-scale MD trajectories of 3CL-Pro, in different states. The application 
and accuracy of the powerful MSM theory has been demonstrated in many cases also by experiments 
that include protein−protein, or protein-drug binding kinetics, as well as protein folding rates and 
protein dynamics (21-24). The application of the MSM method lies in the approximation of the slow 
dynamics of the protein, that are associated with its functionality, in a statistically efficient manner 
and identified a number of important residues among its structure, related also to its dimerization, 
verifying previous data (4).  
To accurately describe the conformational phase space of MPro dimer, we employed the PTmetaD-
WTE method biasing the torsional angles of important residues mentioned in the results section and 
the supplemental material. This latter enhanced sampling technique takes advantage of 
metadynamics simulations which can efficiently push the system under study to sample many minima, 
even if ergodicity is hindered by the shape of the energy landscape. It also takes advantage of the 
replica exchange method, with parallel simulations running at different temperatures (310K-400K). 
The system under study is able to surpass energy barriers at high temperatures, while it cools down 
by exchanges with conformations at lower temperatures. This produces an accurate Free Energy 
Surface (FES) and associated important conformations of MPro were extracted at the FES minima 
(310K) and were thus reported herein.  
Having identified the dynamics of the 3CL-Pro structure, we have used the dimerization interface, as 
a scaffold, for the identification of natural products, impairing molecular dimerization. We have found 
that fortunellin (acacetin 7-O-neohesperidoside), a natural flavonoid O-glycoside, isolated from the 
fruits of Citrus japonica var. margarita (kumquat) (25), binds with high affinity (ΔG -13.9 kcal/mol) to 
the dimerization interface of the 3CL-Pro, and inhibits its dimerization, by interacting with residues 
responsible for the dimerization of the protein. Molecular simulation studies, based on the same MSM 
protocol employed for the unligated protein, revealed important residues that affect the associated 
MPro-Fortunellin dynamics. Some of them, belong to the C44-P52 loop, which has been proposed to 
host mutations, however only at the T45, S46, E47, L50 positions (26). The latter are not listed as 
important residues in the MPro-fortunellin dynamics. This gives us confidence that fortunellin can 
target MPro, even when MPro is mutated. More importantly, in the presence of fortunellin, not all 
MPro conformations are accessible at room temperature. As indicated by the MSM analysis of MPro 
trajectories in the presence of fortunellin, the C1 conformation (crystal structure) is absent, indicating 
that the monomers are trapped in minima inactive for dimerization. 
Previous studies have implicated fortunellin as an activator of anti-oxidant enzymes (HO-1, SOD and 
CAT), through a direct action on Nrf2 and AMPK pathways, considered as important to protect against 
oxidative stress (27). In addition, fortunellin was implicated as a cardioprotective factor in diabetic 
animals (28). Here, we extend the actions of this agent, by reporting a direct effect of fortunellin, 
impairing the dimerization of 3CL-Pro SARS-CoV-2 proteinase, and therefore inhibiting SARS-CoV-2 
replication and proliferation. Interestingly, a number of other natural polyphenols, extracted from the 
ZINC database of natural products share the activity of fortunellin. In details, we have identified  apiin 
(ZINC3983878) and rhoifolin (ZINC3978800) among others, which have been previously studied for 
their biological effects. 
Apiin (apigenin-7-apioglucoside), is a natural flavonoid, a diglycoside of the flavone apigenin, isolated 
from leaves of Apium graveolens var. dulce (celery) and Petroselinum crispum (parsley). Apiin 
extracted from celery exhibited anti-inflammatory properties, as apiin showed strong inhibitory 
activity on inducible nitric oxide synthase (iNOS) expression and nitrite (NO) production when added 
before LPS stimulation of J774.A1 cells (29). In mice models, apiin had a remarkable scavenging activity 
on maleic dialdehyde (MDA) and lipofuscin (LPF), promoted total antioxidant capacity (TAOC) and 
significantly enhanced the activities of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) 
and catalase (CAT)(30), by exerting a radical scavenging activity greater than that of absorbic acid (31) 
and Vitamin E (30). Apiin also showed a marked antihypertensive effect in experimental pulmonary 
hypertension in dogs (32)and anti-influenza virus activity in vitro through inhibition of neuraminidase 
(NA) (33). Besides, the role of apiin cardiovascular activity as antiarrhythmic and anti-ischemic agent 
has also been reported (34). In view of our results, apiin might therefore be a strong drug candidate, 
as it inhibits SARS-CoV-2 virus and tackling also COVID-19 major disease symptoms. 
Rhoifolin (apigenin 7-O-neohesperidoside), is a neohesperidoside, a dihydroxyflavone and a 
glycosyloxyflavone, was first isolated from plant Rhus succedanea (Sumac or wax tree, originating from 
Asia, but also found in Australia and New Zealand) (35). Resently, rhoifolin was found to efficiently 
block the enzymatic activity of SARS-CoV 3CL-Pro (36), with a methodology similar to that used in the 
present study. In addition, rhoifollin was reported to inhibit CVB3 infection, a primary cause of viral 
myocarditis in humans. In addition, it was found to decrease inflammation, by significantly decreasing 
prostaglandin E2 and the release of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) (37, 38). 
Rhoifolin isolated from Citrus grandis leaves was beneficial in metabolic diseases, including type II 
diabetes, by enhancing adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and 
GLUT4 translocation (39). Rhoifolin also caused a decrease of mean aortic pressure, of the arterial and 
pulmonary capillary pressure and of heart rate in the dog (40). Moreover, previous study has 
demonstrated that rhoifolin can have an inhibitory effect on angiotensin-converting enzyme (ACE) 
activity, which plays a key role in the regulation of arterial blood pressure (40). 
 In conclusion, our in silico strategy identified a series of natural flavonoids, which, in the form of drugs 
or dietary supplements, might be an effective strategy against the devastating SARS-CoV-2 infections, 
in humans. 
 
 
  
Methods 
Interrogation of the Swiss Model Biospace (July 2020) resulted in 110 crystal structures of 3CL-Pro, 
bound or not to ligands, and deposited to the Protein Data Bank (https://www.rcsb.org/) (41). Here, 
we have used the crystal with reference 6YB7, representing the dimeric molecule in the absence of a 
ligand. Ligands were retrieved from the ZINC database (http://zinc.docking.org/) (42), usually in a 
canonical smiles format. Fully flexible binding on the GalaxyWeb server (http://galaxy.seoklab.org/), 
and dimerization of the protein were performed as described previously (43). Comparison of 
molecular structures was made with Chimera (44). 
For molecular dynamics studies, the 6YB7, 6LU7 crystals were employed, with Amber03 fields forces 
(45). Classical/ Enhanced samopling MD simulations were performed in GROMACS 2020 (46), for long 
time-periods up to 90 μs, with a time step of 1 fs . Retrieved trajectories were further analyzed by 
Markov state modeling (MSM) (20, 24, 47, 48). Time-structure independent components analysis 
(tICA) was used to reduce the dimentionality of our data, in PyEMMA (49).  
Please, refer to the online Supplement for a detailed description of our methods. 
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Tables and Figures 
Table 1 
Table presents the global and local RMSD values, at the dimerization domain) of 3CL-Pro monomer, 
at different time-frames, as determined by molecular dynamics. The interaction of fortunellin in each 
pose is also shown, as changes of the Gibbs free energy changes (ΔG). 
 
Model 
Time 
(μs) 
RMSD 
Total 
RMSD 
Local 
ΔG 
(kcal/mol) 
0 0 0.000 0.000 -13.936 
1 3 1.637 1.235 -11.199 
2 6 2.248 3.290 -12.144 
3 9 1.954 1.515 -10.704 
4 12 1.421 1.292 -14.213 
5 15 1.756 1.085 -11.611 
6 18 1.706 0.998 -11.987 
7 21 2.292 2.608 -14.658 
8 24 2.694 2.757 -13.699 
9 27 1.845 1.230 -13.563 
10 30 1.821 1.268 -11.468 
11 33 2.031 1.344 -12.760 
12 36 1.924 1.604 -12.518 
13 39 1.888 1.269 -11.579 
14 42 2.544 2.686 -12.165 
15 45 1.897 1.463 -11.507 
16 48 2.122 1.883 -12.423 
17 51 1.965 1.420 -11.478 
18 54 1.924 1.534 -11.997 
19 57 1.915 1.263 -12.070 
20 60 1.874 1.385 -12.660 
 
 
  
Table 2 
ZINC number, formula, SMILES and binding affinity for 3CL-Pro (as expressed by Gibb’s free energy, 
ΔG, change in kcal/mol) of ther sixteen (16) compounds from the ZINC database for natural products. 
 
 
Compound 
 
2D Structure 
 
Smiles 
 
ΔG (Kcal/mol) 
ZINC4349204 
(Fortunellin) 
 
COc1ccc(-
c2cc(=O)c3c(O)cc(O[C
@@H]4O[C@@H](C
O)[C@@H](O)[C@@
H](O)[C@H]4O[C@@
H]4O[C@H](C)[C@H]
(O)[C@H](O)[C@H]4
O)cc3o2)cc1 
-13.936 
ZINC4349029 
 
O=c1cc(-
c2ccc(O)cc2)oc2cc(O[
C@@H]3O[C@@H](C
O)[C@@H](O)[C@H](
O)[C@H]3O[C@@H]3
OC[C@@](O)(CO)[C
@H]3O)cc(O)c12 
-14.241 
ZINC4349031 
 
O=c1cc(-
c2ccc(O)cc2)oc2cc(O[
C@@H]3O[C@H](CO
)[C@@H](O)[C@@H]
(O)[C@H]3O[C@@H]
3OC[C@@](O)(CO)[C
@H]3O)cc(O)c12 
-12.352 
ZINC4349034 
 
O=c1cc(-
c2ccc(O)cc2)oc2cc(O[
C@@H]3O[C@H](CO
)[C@@H](O)[C@H](O
)[C@H]3O[C@@H]3O
C[C@@](O)(CO)[C@
H]3O)cc(O)c12 
-12.451 
ZINC3983878 
(Apiin) 
 
O=c1cc(-
c2ccc(O)cc2)oc2cc(O[
C@@H]3O[C@H](CO
)[C@@H](O)[C@H](O
)[C@H]3O[C@@H]3O
C[C@](O)(CO)[C@H]
3O)cc(O)c12 
-12.604 
ZINC4349207 
 
COc1ccc(-
c2cc(=O)c3c(O)cc(O[C
@@H]4O[C@@H](C
O)[C@@H](O)[C@@
H](O)[C@H]4O[C@@
H]4O[C@@H](C)[C@
H](O)[C@H](O)[C@H
]4O)cc3o2)cc1 
-11.539 
ZINC4349211 
 
COc1ccc(-
c2cc(=O)c3c(O)cc(O[C
@@H]4O[C@@H](C
O)[C@@H](O)[C@@
H](O)[C@H]4O[C@@
H]4O[C@H](C)[C@H]
(O)[C@@H](O)[C@H]
4O)cc3o2)cc1 
-11.545 
ZINC4349214 
 
COc1ccc(-
c2cc(=O)c3c(O)cc(O[C
@@H]4O[C@@H](C
O)[C@@H](O)[C@@
H](O)[C@H]4O[C@@
H]4O[C@@H](C)[C@
H](O)[C@@H](O)[C@
H]4O)cc3o2)cc1 
-12.150 
ZINC4349623 
 
C[C@H]1O[C@@H](
O[C@H]2[C@H](Oc3c
c(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@H](
O)[C@@H](O)[C@H]
1O 
-12.970 
ZINC4349627 
 
C[C@@H]1O[C@@H]
(O[C@H]2[C@H](Oc3
cc(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@H](
O)[C@@H](O)[C@H]
1O 
-13.200 
ZINC4349630 
 
C[C@H]1O[C@@H](
O[C@H]2[C@H](Oc3c
c(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@H](
O)[C@H](O)[C@H]1O 
-12.229 
ZINC4349633 
 
C[C@@H]1O[C@@H]
(O[C@H]2[C@H](Oc3
cc(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@H](
O)[C@H](O)[C@H]1O 
-12.937 
ZINC4534057 
 
C[C@H]1O[C@@H](
O[C@H]2[C@@H](Oc
3cc(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@@H
](O)[C@@H](O)[C@H
]1O 
-12.238 
ZINC4534058 
 
C[C@@H]1O[C@@H]
(O[C@H]2[C@@H](O
c3cc(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@@H
](O)[C@@H](O)[C@H
]1O 
-13.697 
ZINC4534059 
 
C[C@H]1O[C@@H](
O[C@H]2[C@@H](Oc
3cc(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@@H
](O)[C@@H](O)[C@
@H]1O 
-14.387 
ZINC4534060 
 
C[C@@H]1O[C@@H]
(O[C@H]2[C@@H](O
c3cc(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@@H](CO)[C@@H]
(O)[C@H]2O)[C@@H
](O)[C@@H](O)[C@
@H]1O 
-11.160 
ZINC3978800 
(Rhoifolin) 
 
C[C@@H]1O[C@@H]
(O[C@H]2[C@H](Oc3
cc(O)c4c(=O)cc(-
c5ccc(O)cc5)oc4c3)O[
C@H](CO)[C@@H](O
)[C@@H]2O)[C@H](
O)[C@H](O)[C@H]1O 
-11.961 
 
  
 Figure Legends 
Figure 1 
A. MD simulation of 3CL-Pro at a 60 μs scale. Markov state analysis of the monomer conformation 
reveals three main “steady” conformations. Figure presents the location of the obtained three states. 
Ca backbone is presented per state. B. Three conformations of the 3CL-Pro dimer, representing the 
minima of surface dynamic states, as derived by MD, followed by parallel tempering meta-dynamics 
at the well-tempered ensemble. The two monomers are shown in red and green colors and the amino 
acids responsible for the dimerization are shown in blue. 
Figure 2 
A. The molecular structure of fortunellin. B. The interaction of fortunellin with the 3CL-Pro monomer. 
Fortunellin is shown in green, the interacting amino acids are shown in yellow and the dimerization 
interacting aminoacids are shown in blue. Note that fortunellin induces a steric hinderance of 
dimerization, by binding to the same binding interface, responsible for the dimerization of 3CL-Pro. C. 
Changes in the Gibbs free energy (ΔG in kcal/mol) of fortunellin binding on 3CL-Pro monomer and 
RMSD changes of the dimerization interface, as compared to the crystal structure. Poses are 
determined by molecular dynamics of the 3CL-Pro monomer, in a time frame of 60 μs, at 1 fs intervals. 
D. The identified states of MPro in the absence of fortunellin within the refined CV-1, CV-2 phase 
space. E. The identified states of MPro in the presence of fortunellin within the refined CV-1, CV-2 
phase space. The C1 to C3 minima are indicated on the D-E graphs based on the comparison with 
Figure 2B. F-G. The transition times between the C1 to C3 minima are calculated in the absence (F) 
and in the presence (G) of fortunellin. 
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Methods 
Molecular Docking 
SARS-CoV-2 main protease MPro and Ligand Preparation 
The sequence of SARS-CoV-2 main protease MPro, in fasta format, was retrieved from the NCBI 
protein database (https://www.ncbi.nlm.nih.gov/protein/) and introduced to the Swiss Model 
Biospace (http://swissmodel.expasy.org/interactive) (1). The main SARS-CoV-2 protease MPro have 
many available crystal structures and the system, presented in Supplemental Table 1. Codes 
correspond to data stored in the Protein Data Bank (https://www.rcsb.org/) (2). In this work, we have 
used the 6YB7 unliganded crystal, analyzed with X-ray diffraction. Monomers were extracted, using a 
text editor.  
Ligands were retrieved from the ZINC database (http://zinc.docking.org/) (3), in a canonical smiles 
format. Novel molecules were designed in ChemBioDraw (v12.0, Perkin Elmer, Boston, MA, free for 
Academic use from the University of Cambridge). Then, pdb or mol2 files of  the ligands were created 
with the Open Babel program (http://openbabel.org) (4).  
Ligand-MPro docking 
SARS-CoV-2 main protease (in pdb format) and ligand(s) (in mol2 or pdb formats) were uploaded to 
the GalaxyWebserver (http://galaxy.seoklab.org/)  and a fully flexible docking (involving the receptor 
and the ligand) was performed (5-10).  The server uses an algorithm, based on the GalaxyDock2 
docking (11), which, after an automatic prediction of the ligand binding pocket, permits a full 
ligand/receptor flexibility during binding simulation. This step is followed by optimization and 
subsequent refinement, through a specific algorithm named GalaxyRefine (6, 12), which permits a 
protein-ligand structure refinement, by applying iterative side chain repacking and overall structure 
relaxation (6, 13). The best solution (usually denoted as “Model 1”) was retained. The corresponding 
pdb file (containing the MPro-ligand complex) was retrieved. The 3D structures of the liganded and 
unliganded MPro were compared, using the UCSF Chimera 1.11.2 program (14), available from 
https://www.cgl.ucsf.edu/chimera/. The same program was used for comparisons of the retrieved 
solutions with available crystals 
Simulation of MPro dimerization 
1) Dimerization of MPro: The active form of the MPro SARS-CoV-2 main protease, is a homodimer  
(15), as a Cyclic-C2 (Global Symmetry) Homo-2-mer A2 (Global Stoichiometry) (16-19). Here, we used 
two different docking programs to simulate the active dimer and we compare the obtained solutions 
with the crystal 6YB7:  
(1) We used the GalaxyWEB server, routine HOMOMER (http://galaxy.seoklab.org/cgi-
bin/submit.cgi?type=HOMOMER) for the MPro protein oligomer structure prediction from a 
monomer sequence or structure (Ologomeric state = 2). The server carries out template-based 
modeling, ab initio docking or both, depending on the availability of proper oligomer templates, until 
5 models are generated (5).  
(2) We used the Hex 8.0.8 program (http://hex.loria.fr/) (20, 21). Hex 8.0.8, a specialized, locally 
executed, program, for protein-protein, or protein-nucleic acid interactions, based on spherical 
rotated protein complexes, taking into account both surface shape and electrostatic charge. Hex 
returns, through a graphical user interface, a set of >100 solutions, with the corresponding ΔG values. 
The input files for Hex 8.0.8 program are pdb files of MPro with or without ligand and the output file 
is a pdb file that contains the simulated MPro dimer. The 3D structures of the monomer and dimer 
structure of MPro from experimental crystal structures, GalaxyWEB server and Hex 8.0.8 program 
were compared, using the UCSF Chimera 1.11.2 program. The same program was also used to 
determine the dimerization interphase of the monomers. 
Molecular Dynamics computational protocol 
Model setup 
The crystal structures of SARS-CoV-2 main protease MPro, or 3CL-PRO (pdb codes 6LU7(22) 
and 6YB7) were used as initial coordinates to build the models. The pdb structures refer to 
one monomer without and with inhibitor, respectively. For consistency, the inhibitor was 
removed from the crystal structure of MPro (6LU7)(22). Our choice of coordinates was based 
on the completeness of the resolved MPro sequence and the quality of chains (at least 90%). 
To build the MPro dimer, we structurally aligned either two 6lu7, or two 6yb7 monomers on 
a reference dimer.(23) The protonation states of titratable residues were simulated at neutral 
pH, thus all Glu, and Asp residues were left deprotonated, except Glu-290 which was 
protonated, in accordance also with the PDB2PQR (propka 3.0 method, pH 7.3) 
predictions.(24) His-41, His-163, His-172 and His-246 were protonated only at the Nε site. The 
rest of His residues were protonated only at the Νδ sites, to maintain the hydrogen bonding 
network within the crystal structures. All crystallographic water molecules are retained within 
each crystal structure. Four samples were, thus prepared, in a consistent way (two 
monomers, two dimers). The all-atom models, as defined previously, were embedded in 
triclinic boxes of around 7.2nm x 11.2nm x 8.0nm (monomer), or 12.3nm x 12.3 nm x 12.3 nm 
(dimer) in the x, y and z dimensions, respectively. Up to around 57000 TIP3P water 
molecules(25) were used to hydrate each protein. Ion (K+, Cl-) concentration was set at the 
value of 150 mM to mimic the physiological salt content for the monomer or dimer models, 
in addition to zero, or excess concentrations of KCl, NaCl, CaCl2 at 0, 150, 300, 400 and 500 
mM only for the monomer models. The various anionic strengths were only employed to 
indirectly ‘enhance’ the sampled conformational space of the MPro. A surplus of K+ was also 
added to neutralize the protein charges in each sample, resulting in simulation unit boxes of 
62400 (monomer), or 181800 (dimer) atoms. The Amber03(26) protein force field was used 
for the residues and ions. The Amber03 parameters for the natural products were derived 
based on ACPYPE algorithm.(27) 
Equilibration-Production Molecular Dynamics setup 
The equilibration-relaxation for the all-atom systems is employed based on a published 
protocol for water-soluble proteins.(28) This contains a steepest descend energy 
minimization with a tolerance of 0.5 kJ mol-1 for 1000 steps, and a sequence of isothermal 
(nVT), isothermal-isobaric (nPT) runs with the gradual relaxation of the constraints on protein 
heavy atoms (from 104 in steps1-2 to 103 kJ mol-1 nm-2 in step-4) and Cα atoms (from 103 in 
step-5, to 102 in step-6, 10 in step-7, 1 in step-8 and 0 kJ mol-1 nm-2 in step-9) for around 30 
ns, with a time step of 1.0 fs (steps 1-4) and 2.0 fs (steps 5-9). In detail: (step-1) Constant 
density and temperature (nVT) Brownian dynamics (BD) at 100 K for 50 ps that employs the 
Berendsen thermostat,(29) with a temperature coupling constant at 1.0 fs. (steps 2-3) Two 
short constant density (nVT) and constant pressure (nPT) runs for 100 ps each, with a weak 
coupling Berendsen thermostat and barostat(29) at 100 K employing time coupling constants 
of 0.1 ps for the temperature and isotropic 50.0 ps coupling for the pressure with a 
compressibility of 4.6x10-5. (step-4) Heating from 100 to 250 K in a constant density ensemble 
(nVT) for 3 ns employing the v-rescale thermostat,(30) with a time coupling constant of 0.1 
ps. (step-5) Heating from 250 to 310K in a constant pressure ensemble (nPT) for 2 ns, 
employing the v-rescale thermostat(30) and Berendsen barostat,(29) with time coupling 
constants of 0.1 ps for the temperature and 2.0 ps for the pressure, removing also all but the 
Cα-atom protein position restraints. (step-6) Equilibration at 310K (0.1 ps temperature 
coupling constant) for 5 ns (nPT, 1 atm, 2.0 ps coupling constant for pressure. (steps 7-8) 
Equilibration at 310K (0.5 ps temperature coupling constant) for 5 ns (nPT, 1 atm, 2.0 ps 
coupling constant for pressure). (step-9) Equilibration at 310K (0.5 ps temperature coupling 
constant) for 10 ns (nPT, 1 atm, 2.0 ps coupling constant for pressure). The barostats – 
thermostats employed for steps 6-9 were the same as in the production trajectories that 
follow. 
For the production all-atom classical Molecular Dynamics (MD), the Newton’s equations of 
motion are integrated with a time step of 2.0 fs at 310K. All production simulations are run 
with the leap-frog integrator in GROMACS 2020(31) for 3.0 μs each. They were performed at 
the constant pressure nPT ensemble, with isotropic coupling (compressibility at 4.5x10-5) 
employing the v-rescale thermostat(30) (310K, temperature coupling constant 0.5) and the 
Parrinello-Rahman barostat(32) (1 atm, pressure coupling constant 2.0). Details for 
parameters can be found in earlier work.(28) The first 500 ns were considered further 
equilibration from each independent trajectory per sample, and were disregarded in the 
analysis. Van der Waals interactions were smoothly switched to zero between 1.0-1.2 nm with 
the VERLET cut-off scheme. Electrostatic interactions were truncated at 1.2 nm (short-range) 
and long-range contributions were computed within the PME approximation.(33, 34) 
Hydrogen bond lengths were constrained employing the LINCS algorithm.(35) 
Markov State Model Analysis 
We obtained a series of MD equilibrium trajectories of the MPro monomers (60μs) of SARS-
CoV-2 main protease under different salts/ ionic strengths, without inhibitors. These should 
have explored a major part of the MPro conformational phase space. We combined the all-
atom MD simulations with Markov state model (MSM) theory(36-38) in order to enable the 
extraction of long-time-scale individual monomer dynamics from rather short-time-scale MD 
trajectories of different states. The application and accuracy of the powerful MSM theory has 
been presented in many cases also by experiments that include protein−protein, or protein-
drug binding kinetics, as well as protein folding rates and protein dynamics.(39-42) Our 
objective was to approximate the slow dynamics in a statistically efficient manner. Thus, a 
lower dimensional representation of our simulation data was necessary. In order to reduce 
the dimensionality of our feature space, we employed the time-structure independent 
components analysis (tICA) which yields a representation of our molecular simulation data 
with a reduced dimensionality and can greatly facilitate the decomposition of our system into 
the discrete Markovian states necessary for MSM estimation. The conformations of the 
system were projected on these slowest modes as defined by the tICA method, then the 
trajectory frames were clustered into 100 cluster-centers (microstates) by k-means clustering, 
as implemented in PyEMMA.(43) Conformational changes of a system can be simulated as a 
Markov chain, if the transitions between the different conformations are sampled at long 
enough time intervals so that each transition is Markovian. This means that a transition from 
one conformation to another is independent of the previous transitions. Therefore, an MSM 
is a memoryless model. The uncertainty bounds were computed using a Bayesian scheme.(44, 
45) We found that the slowest implied timescales converge quickly and are constant within a 
95% confidence interval for lag times above 50ns. The validation procedure is a standard 
approach in the MSM field., a lag time of 50 ns was selected for Bayesian model construction, 
and the resulting models were validated by the Chapman-Kolmogorov (CK) test. 
Subsequently, the resulting MSMs were further coarse grained into a smaller number of three 
metastable states or microstates, using PCCA++ as implemented in PyEMMA.(43) The 
optimum number of microstates (three) was proposed based on the VAMP2-score.(46) Both 
the convergence of the implied timescales, as well as the CK test confirm the validity and 
convergence of the MSM. The CK test indicates that predictions from the built MSM agree 
well with MSMs estimated with longer lag times. Thus, the model can describe well the long-
time-scale behavior of our system within error. The tICA method identified the torsional 
angles of the following MPro residues: 3, 4, 5, 6, 84, 135, 141, 164, 167, 171, 175, 178, 179, 
180, 190, 195, 217, 284, 285, 286, 290, 291, 300, and 301 as the most important features, by 
setting a series of thresholds for the coefficients in the tICA vectors. At first, we set a threshold 
of 0.09. We continued by setting a threshold of 0.04 for the coefficients in the tICA vectors of 
the filtered data and afterwards a threshold of 0.085. Finally, we set a threshold of 0.075 and 
thus we concluded in the previously referred MPro residues. For the selection of these 
thresholds we checked for different thresholds the VAMP2-score and the states projected 
onto the first two independent components.  We report the exact functions of the first two 
tICA components, as a linear combination of cosine/ sine functions of the associated 
torsionals: 
CV1 = (0.22245479085963174)*COS(PHE3PHI)+(-
0.16733307515910162)*SIN(PHE3PHI)+(0.1432275835003262)*COS(PHE3PSI)+(0.200886899869637
5)*SIN(PHE3PSI)+(0.19936685751147043)*COS(ARG4PHI)+(-
0.09327647115497929)*SIN(ARG4PHI)+(-0.0930358300031665)*COS(ARG4PSI)+(-
0.08538905470780045)*SIN(ARG4PSI)+(0.10166329580502668)*COS(LYS5PHI)+(-
0.09568173783678022)*SIN(LYS5PHI)+(-0.09287774945984135)*COS(LYS5PSI)+(-
0.15790698786616095)*SIN(LYS5PSI)+(-
0.0956189898931311)*COS(MET6PHI)+(0.025245999648597445)*SIN(MET6PHI)+(0.0408771827310
96175)*COS(MET6PSI)+(-
0.0006973055782739627)*SIN(MET6PSI)+(0.12585421365826116)*COS(ASN84PHI)+(0.1980318831
213358)*SIN(ASN84PHI)+(0.08785335907805712)*COS(ASN84PSI)+(-
0.1678608618927701)*SIN(ASN84PSI)+(0.3615169358035203)*COS(THR135PHI)+(0.2355840179344
413)*SIN(THR135PHI)+(0.06937744998780684)*COS(THR135PSI)+(-
0.08624991337144639)*SIN(THR135PSI)+(0.06993246492427758)*COS(LEU141PHI)+(-
0.023980684220480688)*SIN(LEU141PHI)+(-0.0028980923592885344)*COS(LEU141PSI)+(-
0.11124570694911744)*SIN(LEU141PSI)+(0.12367941924553509)*COS(HIS164PHI)+(0.1100289626
0080477)*SIN(HIS164PHI)+(0.1736049601096124)*COS(HIS164PSI)+(-
0.10071229902364524)*SIN(HIS164PSI)+(0.04589771207808335)*COS(LEU167PHI)+(0.0319038117
3082644)*SIN(LEU167PHI)+(0.010408062573537607)*COS(LEU167PSI)+(-
0.001452825004362783)*SIN(LEU167PSI)+(-
0.035449253177574046)*COS(VAL171PHI)+(0.0397831323983392)*SIN(VAL171PHI)+(-
0.01487903934140085)*COS(VAL171PSI)+(-
0.034102380825128384)*SIN(VAL171PSI)+(0.030847079909921624)*COS(THR175PHI)+(-
0.020040648643118112)*SIN(THR175PHI)+(0.12177024626152966)*COS(THR175PSI)+(-
0.13229839249150296)*SIN(THR175PSI)+(0.11507939509465313)*COS(GLU178PHI)+(0.1013714392
35159)*SIN(GLU178PHI)+(-
0.09137875539957069)*COS(GLU178PSI)+(0.11214339094322172)*SIN(GLU178PSI)+(-
0.09294920607798879)*COS(GLY179PHI)+(0.28997810094722837)*SIN(GLY179PHI)+(-
0.27573006050671983)*COS(GLY179PSI)+(-
0.09673320535071989)*SIN(GLY179PSI)+(0.010926172367439396)*COS(ASN180PHI)+(-
0.24668920154301732)*SIN(ASN180PHI)+(-
0.14912645633298552)*COS(ASN180PSI)+(0.3816102785675176)*SIN(ASN180PSI)+(-
0.10964069317986454)*COS(THR190PHI)+(-0.009927774218497826)*SIN(THR190PHI)+(-
0.16097973924205633)*COS(THR190PSI)+(-
0.16639818413751062)*SIN(THR190PSI)+(0.08017482811083185)*COS(GLY195PHI)+(-
0.14979887114706295)*SIN(GLY195PHI)+(-0.050958292897186695)*COS(GLY195PSI)+(-
0.044354361874655926)*SIN(GLY195PSI)+(0.09987054135337944)*COS(ARG217PHI)+(-
0.12648381947691048)*SIN(ARG217PHI)+(0.08158948319042672)*COS(ARG217PSI)+(-
0.00021426690460247595)*SIN(ARG217PSI)+(0.21642336166830292)*COS(SER284PHI)+(-
0.30155833144467264)*SIN(SER284PHI)+(0.8266406109913902)*COS(SER284PSI)+(0.88748800878
14281)*SIN(SER284PSI)+(0.6649555215066218)*COS(ALA285PHI)+(0.44940445619426095)*SIN(ALA
285PHI)+(-0.7837894441282054)*COS(ALA285PSI)+(-0.7618813787744232)*SIN(ALA285PSI)+(-
0.41060021549010234)*COS(LEU286PHI)+(-
0.10014769031761044)*SIN(LEU286PHI)+(0.19732367941536325)*COS(LEU286PSI)+(0.2864165371
4402343)*SIN(LEU286PSI)+(0.2011752565537491)*COS(GLU290PHI)+(0.08698680780975648)*SIN(
GLU290PHI)+(-
0.00570069571470415)*COS(GLU290PSI)+(0.06637101699247436)*SIN(GLU290PSI)+(0.2298963479
5972827)*COS(PHE291PHI)+(-0.17343642924439104)*SIN(PHE291PHI)+(-
0.11571250082711405)*COS(PHE291PSI)+(0.02324511232530362)*SIN(PHE291PSI)+(-
0.047478679669659275)*COS(CYS300PHI)+(0.05578968284901458)*SIN(CYS300PHI)+(-
0.1683363737052317)*COS(CYS300PSI)+(-0.2973909304454135)*SIN(CYS300PSI)+(-
0.1038665536799251)*COS(SER301PHI)+(-0.019617745122528882)*SIN(SER301PHI)+(-
0.06934626053471138)*COS(SER301PSI)+(-0.10587162831562456)*SIN(SER301PSI) 
 
CV2 = (-0.2884241825864551)*COS(PHE3PHI)+(0.1818110423100234)*SIN(PHE3PHI)+(-
0.4677450443427827)*COS(PHE3PSI)+(-0.5483897439796918)*SIN(PHE3PSI)+(-
0.3553107265200588)*COS(ARG4PHI)+(-0.22394962064864046)*SIN(ARG4PHI)+(-
0.270179755725878)*COS(ARG4PSI)+(-0.3829402238055943)*SIN(ARG4PSI)+(-
0.2042142888426065)*COS(LYS5PHI)+(-
0.1669302788926349)*SIN(LYS5PHI)+(0.141973243784881)*COS(LYS5PSI)+(0.1421901057216299)*
SIN(LYS5PSI)+(0.0846185601658726)*COS(MET6PHI)+(0.20450776328031908)*SIN(MET6PHI)+(-
0.03312223507339774)*COS(MET6PSI)+(-0.08043115352475075)*SIN(MET6PSI)+(-
0.027921418396744165)*COS(ASN84PHI)+(-0.08339140826693826)*SIN(ASN84PHI)+(-
0.38318457142235807)*COS(ASN84PSI)+(-0.02014396174778721)*SIN(ASN84PSI)+(-
0.261602759573732)*COS(THR135PHI)+(-0.22169542813755444)*SIN(THR135PHI)+(-
0.087566095559111)*COS(THR135PSI)+(0.11762076691089288)*SIN(THR135PSI)+(-
0.3469970284275915)*COS(LEU141PHI)+(0.34989926232122653)*SIN(LEU141PHI)+(-
0.3353014777111922)*COS(LEU141PSI)+(-0.1099813590134305)*SIN(LEU141PSI)+(-
0.030401089904733867)*COS(HIS164PHI)+(-0.12811671967132546)*SIN(HIS164PHI)+(-
0.13436881803853637)*COS(HIS164PSI)+(0.17139820505530204)*SIN(HIS164PSI)+(-
0.12200117274899505)*COS(LEU167PHI)+(-0.06149505441676782)*SIN(LEU167PHI)+(-
0.06260851492073659)*COS(LEU167PSI)+(0.06084287820758976)*SIN(LEU167PSI)+(-
0.006861594758294066)*COS(VAL171PHI)+(0.012827540881062702)*SIN(VAL171PHI)+(0.01246408
7205759892)*COS(VAL171PSI)+(-
0.02648078463371077)*SIN(VAL171PSI)+(0.13636122184567023)*COS(THR175PHI)+(-
0.16662872008089358)*SIN(THR175PHI)+(0.005026593046059509)*COS(THR175PSI)+(-
0.020823512651369957)*SIN(THR175PSI)+(-0.15569457005305837)*COS(GLU178PHI)+(-
0.12910762053786512)*SIN(GLU178PHI)+(0.195962425618426)*COS(GLU178PSI)+(-
0.1674075865238855)*SIN(GLU178PSI)+(-0.05538839797914528)*COS(GLY179PHI)+(-
0.2984068151828335)*SIN(GLY179PHI)+(0.4196490331550077)*COS(GLY179PSI)+(0.209794540149
4899)*SIN(GLY179PSI)+(-
0.021574332218825033)*COS(ASN180PHI)+(0.3273623222055997)*SIN(ASN180PHI)+(0.087178704
14956289)*COS(ASN180PSI)+(-0.47359288885540496)*SIN(ASN180PSI)+(-
0.04538558390983336)*COS(THR190PHI)+(-
0.008683270082020167)*SIN(THR190PHI)+(0.271129910670838)*COS(THR190PSI)+(0.27549665651
127636)*SIN(THR190PSI)+(0.0780842690641956)*COS(GLY195PHI)+(0.044233409296374225)*SIN(
GLY195PHI)+(0.13353598315320972)*COS(GLY195PSI)+(0.04465259963400809)*SIN(GLY195PSI)+(0
.027701779053662518)*COS(ARG217PHI)+(0.03397617632773808)*SIN(ARG217PHI)+(-
0.055406779213062196)*COS(ARG217PSI)+(-
0.15249136969809435)*SIN(ARG217PSI)+(0.15917442405868654)*COS(SER284PHI)+(0.0731739530
9230672)*SIN(SER284PHI)+(0.050094307429749026)*COS(SER284PSI)+(0.19617816860701598)*SI
N(SER284PSI)+(0.1826732916695155)*COS(ALA285PHI)+(-
0.035338601991516574)*SIN(ALA285PHI)+(-0.19924762948366187)*COS(ALA285PSI)+(-
0.1564466277523662)*SIN(ALA285PSI)+(-0.0443686239963879)*COS(LEU286PHI)+(-
0.10931048704118541)*SIN(LEU286PHI)+(0.45176938273388506)*COS(LEU286PSI)+(0.4751207479
763982)*SIN(LEU286PSI)+(0.1954750353189944)*COS(GLU290PHI)+(0.28698450313441914)*SIN(G
LU290PHI)+(0.1178561297010931)*COS(GLU290PSI)+(-0.11293348016651641)*SIN(GLU290PSI)+(-
0.23109368829696822)*COS(PHE291PHI)+(0.2905179445957612)*SIN(PHE291PHI)+(0.2414087396
867373)*COS(PHE291PSI)+(-0.19323071296694158)*SIN(PHE291PSI)+(-
0.06723387446469688)*COS(CYS300PHI)+(0.08472356860436044)*SIN(CYS300PHI)+(0.1128690279
3988102)*COS(CYS300PSI)+(0.33756361790231243)*SIN(CYS300PSI)+(0.07472554678618155)*COS(
SER301PHI)+(-
0.04927948273422832)*SIN(SER301PHI)+(0.13667888455911714)*COS(SER301PSI)+(0.1947392228
687667)*SIN(SER301PSI) 
The residues that seem to affect the MPro-fortunellin dynamics are derived based on the 
same MSM/ tICA protocol described before in the absence of the inhibitor. These include: 44, 
48, 53, 82, 83, 84, 111, 112, 118, 137, 138, 139, 141, 159, 182, 238, 239, 240, 286, 287, 288, 
289, 291. At first, we set a threshold of 0.075. We continued by setting a threshold of 0.12 for 
the coefficients in the tICA vectors of the filtered data, a threshold of 0.18, a threshold of 
0.065 and afterwards a threshold of 0.135. Finally, we set a threshold of 0.125 and thus we 
concluded in the previously referred residues. However, the MPro states in the presence of 
fortunellin, reported in Figure 2E of the main manuscript, are derived based on the projection 
of the Mpro-fortunellin trajectory data on the aforementioned phase space of the CV1, CV2 
functions. 
 
Enhanced Molecular Dynamics Sampling 
To enhance the conformational sampling on the MPro dimer we employed the parallel 
tempering metadynamics in the well-tempered ensemble (PTmetaD-WTE) method.(47-50) 
Nine replicas per sample were run at 310, 320, 330, 341, 352, and 363K, 375K, 387K and 400K 
in which only the potential energy (PE) was initially biased (bias factor 120) to achieving large 
fluctuations in PE and replica overlaps. Replicas were allowed to exchange every 1000 steps 
for 0.2μs each, which gave an exchange probability around 20% in the WTE. The obtained bias 
was saved and used for the subsequent PTmetaD production runs for another 0.5μs per 
sample/ replica. Nine replicas were again considered at the same temperatures. Including the 
equilibration time at reach replica, a cumulative simulation time of 10μs was achieved. An 
exchange was attempted every 1000 steps, that gave an exchange probability between 
replicas at around 20%, consistent with the large sample sizes. The Collective Variables (CVs) 
chosen for the PTmetaD runs were the first two tICA vectors presented above (CV1/ CV2). A 
combination of the GROMACS 2020/ PLUMED 2.5(51) engines was employed. A bias factor of 
25 at the well-tempered ensemble, along with Gaussians of 1.2 kJ/mol initial height, and 
sigma values (width) of 0.25 in the CV space, deposited every 2 ps, was employed. The grid 
space for both CVs is defined between -4 to 4 at a resolution of 0.05. Four different PTmetaD-
WTE runs were performed for the pdb 6yb7/ 6lub7 -based dimers at 150mM KCl without 
inhibitor. 
Supplemental Table 1 
PDB codes of 3CL-PRO crystals, deposited in the PDB databank, accessed at July 3, 2020. 
5r7y, 5r7z, 5r80, 5r81, 5r82, 5r83, 5r84, 5r8t, 5re4, 5re5, 5re6, 5re7, 5re8, 5re9, 5rea, 5reb, 5rec, 5red, 
5ree, 5ref, 5reg, 5reh, 5rei, 5rej, 5rek, 5rel, 5rem, 5ren, 5reo, 5rep, 5rer, 5res, 5ret, 5reu, 5rev, 5rew, 
5rex, 5rey, 5rez, 5rf0, 5rf1, 5rf2, 5rf3, 5rf4, 5rf5, 5rf6, 5rf7, 5rf8, 5rf9, 5rfa, 5rfb, 5rfc, 5rfd, 5rfe, 5rff, 
5rfg, 5rfh, 5rfi, 5rfj, 5rfk, 5rfl, 5rfm, 5rfn, 5rfo, 5rfp, 5rfq, 5rfr, 5rfs, 5rft, 5rfu, 5rfv, 5rfw, 5rfx, 5rfy, 5rfz, 
5rg0, 5rg1, 5rg2, 5rg3, 5rgg, 5rgh, 5rgi, 5rgj, 5rgk, 5rgl, 5rgm, 5rgn, 5rgo, 5rgp, 5rgq, 5rgr, 5rgs, 5rgt, 
5rgu, 5rgv, 5rgw, 5rgx, 5rgy, 5rgz, 5rh0, 5rh1, 5rh2, 5rh3, 5rh4, 5rh5, 5rh6, 5rh7, 5rh8, 5rh9, 5rha, 
5rhb, 5rhc, 5rhd, 5rhe, 5rhf, 6lu7, 6lze, 6m03, 6m0k, 6m2n, 6m2q, 6w63, 6wnp, 6wqf, 6wtj, 6wtk, 
6wtm, 6wtt, 6xa4, 6xb0, 6xb1, 6xb2, 6xbg, 6xbh, 6xbi, 6xch, 6y2e, 6y2f, 6y2g, 6y84, 6yb7, 6ynq, 6yt8, 
6yvf, 6yz6, 6z2e, 7bqy, 7bro, 7brp, 7brr, 7buy, 7c8r, 7c8t 
 
  
Supplemental Table 2 
ADME characteristics of 16 compounds from the ZINC database for natural products, evaluated with 
the SwissADME resource (52). 
See SwissADME.xlsx file 
 
 
  
Supplemental Figure 1 
 
 
 
 
Superposition of 10 different 3CL-PRO models, from the PDB database. RMSDs were calculated with 
the Chimera program (14). 
  
Supplemental Figure 2 
 
 
Comparison of the crystal structure (pdb 6YB7) with the two simulated solutions obtained with the 
GalaxyWeb (routine homomer) (5) and the HEX program (20, 21). The distinct colors in each Figure 
shows the corresponding monomers. 
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Molecule Smiles Canonical SMILES Formula MW #Heavy atoms #Aromatic heavy atoms Fraction Csp3 #Rotatable bonds #H‐bond acceptors #H‐bond donors MR TPSA
ZINC4349204 (Fortunellin) C[C@@H]1[C@@H]([C@@H]([C@HOC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)OC)[C@@H]([C@@H]([C@@H]1O)O)O C28H32O14 592.55 42 16 0.46 7 14 7 141.80 217.97
ZINC4349029 c1cc(ccc1c2cc(=O)c3c(cc(cc3o2)O[C@OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@H]([C@@H]1O)O)O[C@C26H28O14 564.49 40 16 0.42 7 14 8 132.56 228.97
ZINC4349031 c1cc(ccc1c2cc(=O)c3c(cc(cc3o2)O[C@OC[C@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[C@C26H28O14 564.49 40 16 0.42 7 14 8 132.56 228.97
ZINC4349034 c1cc(ccc1c2cc(=O)c3c(cc(cc3o2)O[C@OC[C@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@C26H28O14 564.49 40 16 0.42 7 14 8 132.56 228.97
ZINC3983878 c1cc(ccc1c2cc(c‐3c(=O)cc(cc3o2)O[COC[C@H]1O[C@@H](Oc2cc(=O)c3c(c2)oc(cc3[O‐])c2ccc(cc2)O)[C@@H]([C@H]([C@@H]1O)O)O[C@C26H27O14 563.48 40 16 0.42 7 14 7 129.79 231.80
ZINC4349207 C[C@H]1[C@@H]([C@@H]([C@H]([OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)OC)[C@@H]([C@@H]([C@@H]1O)O)O C28H32O14 592.55 42 16 0.46 7 14 7 141.80 217.97
ZINC4349211 C[C@@H]1[C@@H]([C@H]([C@H]([OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)OC)[C@@H]([C@@H]([C@@H]1O)O)O C28H32O14 592.55 42 16 0.46 7 14 7 141.80 217.97
ZINC4349214 C[C@H]1[C@@H]([C@H]([C@H]([C@OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)OC)[C@@H]([C@@H]([C@@H]1O)O)O C28H32O14 592.55 42 16 0.46 7 14 7 141.80 217.97
ZINC4349623 C[C@@H]1[C@@H]([C@@H]([C@HOC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[CC27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC4349627 C[C@H]1[C@@H]([C@@H]([C@H]([OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[CC27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC4349630 C[C@@H]1[C@@H]([C@H]([C@H]([OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[CC27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC4349633 C[C@H]1[C@@H]([C@H]([C@H]([C@OC[C@@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[CC27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC4534057 C[C@@H]1[C@@H]([C@@H]([C@@OC[C@@H]1O[C@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[C@C27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC4534058 C[C@H]1[C@@H]([C@@H]([C@@HOC[C@@H]1O[C@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[C@C27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC4534059 C[C@@H]1[C@H]([C@@H]([C@@HOC[C@@H]1O[C@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[C@C27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC4534060 C[C@H]1[C@H]([C@@H]([C@@H]([OC[C@@H]1O[C@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@@H]([C@@H]1O)O)O[C@C27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
ZINC3978800 C[C@H]1[C@@H]([C@H]([C@H]([C@OC[C@H]1O[C@@H](Oc2cc(O)c3c(c2)oc(cc3=O)c2ccc(cc2)O)[C@@H]([C@H]([C@@H]1O)O)O[C@@C27H30O14 578.52 41 16 0.44 6 14 8 137.33 228.97
Fraction Csp3 The ratio of sp3 hybridized carbons over the total carbon count of the molecule
MR Molecular refractivity
TPSA Topological polar surface area
iLOGP Efficient Description of n‐Octanol/Water Partition Coefficient
XLOGP3 XLOGP3 predicts the logP value of a query compound by using the known logP value of a reference compound as a starting point.
WLOGP Lipophilicity factor developed by Wildman and Crippen
MLOGP Octanol/water partition coefficient developed by Moriguchi and Matsushita
Silicos‐IT Log P SILICOS‐IT is the log Po/w estimation returned by executing the FILTER‐IT program
Consensus Log P Consensus log Po/w value is the arithmetic mean of the five predictive values above
ESOL Log S Solubility, log S (calculated with the ESOL model) ‐ Estimating Aqueous Solubility Directly from Molecular Structure
ESOL Solubility (mg/ml) Estimating Aqueous Solubility Directly from Molecular Structure in mg/ml
ESOL Solubility (mol/l) Estimating Aqueous Solubility Directly from Molecular Structure in mol/l
ESOL Class Classification of the compound based on estimating Aqueous Solubility Directly from Molecular Structure
Ali Log S In silico prediction of aqueous solubility incorporating the effect of topographical polar surface area by Ali et all.
Ali Solubility (mg/ml) Aqueous Solubility developed by Ali in mg/ml
Ali Solubility (mol/l) Aqueous Solubility developed by Ali in mol/l
Ali Class Classification of the compound based on estimating Aqueous Solubility by Ali
Silicos‐IT LogSw Intrinsic water solubility estimated by Wskowwin executing the FILTER‐IT program
Silicos‐IT Solubility (mg/ml) Intrinsic water solubility in mg/ml
Silicos‐IT Solubility (mol/l) Intrinsic water solubility in mol/l
Silicos‐IT class Classification of the compound based on the water solubility  executing the FILTER‐IT program
log Kp (cm/s) Value of the skin permeability coefficient
iLOGP XLOGP3 WLOGP MLOGP Silicos‐IT Log P Consensus Log P ESOL Log S ESOL Solubility (mg/ml) ESOL Solubility (mol/l) ESOL Class Ali Log S Ali Solubility (mg/ml) Ali Solubility (mol/l) Ali Class Silicos‐IT LogSw Silicos‐IT Solubility (mg/ml) Silicos‐IT Solubility (mol/l) Silicos‐IT class
3.12 1.05 ‐0.80 ‐2.76 ‐0.62 0.00 ‐4.00 5.99e‐02 1.01e‐04 Soluble ‐5.22 3.59e‐03 6.05e‐06 Moderately soluble ‐2.16 4.06e+00 6.85e‐03 Soluble
1.85 ‐0.36 ‐1.49 ‐3.16 ‐0.72 ‐0.77 ‐2.95 6.38e‐01 1.13e‐03 Soluble ‐3.99 5.83e‐02 1.03e‐04 Soluble ‐1.92 6.83e+00 1.21e‐02 Soluble
2.11 ‐0.36 ‐1.49 ‐3.16 ‐0.72 ‐0.72 ‐2.95 6.38e‐01 1.13e‐03 Soluble ‐3.99 5.83e‐02 1.03e‐04 Soluble ‐1.92 6.83e+00 1.21e‐02 Soluble
2.16 ‐0.36 ‐1.49 ‐3.16 ‐0.72 ‐0.71 ‐2.95 6.38e‐01 1.13e‐03 Soluble ‐3.99 5.83e‐02 1.03e‐04 Soluble ‐1.92 6.83e+00 1.21e‐02 Soluble
2.92 ‐1.04 ‐1.10 ‐3.39 ‐0.72 ‐0.67 ‐2.51 1.73e+00 3.07e‐03 Soluble ‐3.34 2.58e‐01 4.57e‐04 Soluble ‐1.92 6.82e+00 1.21e‐02 Soluble
3.09 1.05 ‐0.80 ‐2.76 ‐0.62 ‐0.01 ‐4.00 5.99e‐02 1.01e‐04 Soluble ‐5.22 3.59e‐03 6.05e‐06 Moderately soluble ‐2.16 4.06e+00 6.85e‐03 Soluble
2.94 1.05 ‐0.80 ‐2.76 ‐0.62 ‐0.04 ‐4.00 5.99e‐02 1.01e‐04 Soluble ‐5.22 3.59e‐03 6.05e‐06 Moderately soluble ‐2.16 4.06e+00 6.85e‐03 Soluble
2.74 1.05 ‐0.80 ‐2.76 ‐0.62 ‐0.08 ‐4.00 5.99e‐02 1.01e‐04 Soluble ‐5.22 3.59e‐03 6.05e‐06 Moderately soluble ‐2.16 4.06e+00 6.85e‐03 Soluble
2.45 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.59 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
2.03 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.67 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
2.61 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.56 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
2.60 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.56 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
2.45 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.59 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
2.63 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.55 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
2.57 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.56 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
2.20 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.64 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
1.31 ‐0.16 ‐1.10 ‐2.96 ‐1.17 ‐0.81 ‐3.22 3.50e‐01 6.04e‐04 Soluble ‐4.19 3.70e‐02 6.40e‐05 Moderately soluble ‐1.48 1.92e+01 3.31e‐02 Soluble
GI absorption BBB permeant Pgp substrate CYP1A2 inhibitor CYP2C19 inhibitor CYP2C9 inhibitor CYP2D6 inhibitor CYP3A4 inhibitor log Kp (cm/s) Lipinski #violations Ghose #violations Veber #violations Egan #violations Muegge #violations Bioavailability Score PAINS #alerts Brenk #alerts
Low No Yes No No No No No ‐9.17 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐10.00 3 3 1 1 3 0.17 0 0
Low No Yes No No No No No ‐10.00 3 3 1 1 3 0.17 0 0
Low No Yes No No No No No ‐10.00 3 3 1 1 3 0.17 0 0
Low No Yes No No No No No ‐10.48 3 2 1 1 3 0.11 0 0
Low No Yes No No No No No ‐9.17 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.17 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.17 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Low No Yes No No No No No ‐9.94 3 4 1 1 3 0.17 0 0
Leadlikeness #violations Synthetic Accessibility
1 6.45
1 6.08
1 6.08
1 6.08
1 6.28
1 6.45
1 6.45
1 6.45
1 6.33
1 6.33
1 6.33
1 6.33
1 6.33
1 6.33
1 6.33
1 6.33
1 6.33
